Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series.

Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, van Oort IM, van Basten JP, Karthaus HF, Witjes JA, Barentsz JO.

Invest Radiol. 2012 Mar;47(3):153-8. doi: 10.1097/RLI.0b013e31823ea1f0.

PMID:
22293513
2.

Downstaging of TURBT-Based Muscle-Invasive Bladder Cancer by Radical Cystectomy Predicts Better Survival.

van Dijk PR, Ploeg M, Aben KK, Weijerman PC, Karthaus HF, van Berkel JT, Viddeleer AC, Geboers A, van Boven E, Witjes JA, Kiemeney LA.

ISRN Urol. 2011;2011:458930. doi: 10.5402/2011/458930. Epub 2011 Apr 27.

3.

Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia.

Robert G, Smit F, Hessels D, Jannink S, Karthaus HF, Aalders T, Jansen K, de la Taille A, Mulders PF, Schalken JA.

Prostate. 2011 Nov;71(15):1701-9. doi: 10.1002/pros.21387. Epub 2011 Mar 28.

PMID:
21446005
4.

Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer.

Kok DE, van Roermund JG, Aben KK, van de Luijtgaarden MW, Karthaus HF, van Vierssen Trip OB, Kampman E, Alfred Witjes J, Kiemeney LA.

World J Urol. 2011 Oct;29(5):695-701. doi: 10.1007/s00345-010-0629-0. Epub 2010 Dec 16.

5.

Brachytherapy versus cystectomy in solitary bladder cancer: a case control, multicentre, East-Netherlands study.

van der Steen-Banasik E, Ploeg M, Witjes JA, van Rey FS, Idema JG, Heijbroek RP, Karthaus HF, Reinders JG, Viddeleer A, Visser AG.

Radiother Oncol. 2009 Nov;93(2):352-7. doi: 10.1016/j.radonc.2009.04.020. Epub 2009 May 18.

PMID:
19457565
6.

Impact of obesity on surgical outcomes following open radical prostatectomy.

van Roermund JG, van Basten JP, Kiemeney LA, Karthaus HF, Witjes JA.

Urol Int. 2009;82(3):256-61. doi: 10.1159/000209353. Epub 2009 May 11.

PMID:
19440009
7.

Allelic imbalance analysis using a single-nucleotide polymorphism microarray for the detection of bladder cancer recurrence.

Coenen MJ, Ploeg M, Schijvenaars MM, Cornel EB, Karthaus HF, Scheffer H, Witjes JA, Franke B, Kiemeney LA.

Clin Cancer Res. 2008 Dec 15;14(24):8198-204. doi: 10.1158/1078-0432.CCR-08-1103.

8.

The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study.

van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, Witjes JA, Schalken JA.

Prostate. 2007 Sep 15;67(13):1432-8.

PMID:
17639504
9.

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.

van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA.

Clin Cancer Res. 2007 Feb 1;13(3):939-43.

10.

UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.

Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA.

Eur Urol. 2007 May;51(5):1275-80; discussion 1280. Epub 2006 Oct 30.

PMID:
17084511
11.

Testicular granulocytic sarcoma without systemic leukemia.

Lagerveld BW, Wauters CA, Karthaus HF.

Urol Int. 2005;75(1):94-6.

PMID:
16037717
12.

[Diagnostic image (234). A man with an acute scrotum].

van Roermund JG, Karthaus HF.

Ned Tijdschr Geneeskd. 2005 Apr 2;149(14):758. Dutch.

PMID:
15835627
13.

Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas.

Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, Swinkels DW, Gunnewiek JM, de Kok JB.

Clin Chem. 2004 Aug;50(8):1425-8. No abstract available.

PMID:
15277352
14.

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA.

Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6.

PMID:
12814669
15.

DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB.

Cancer Res. 1999 Dec 1;59(23):5975-9.

16.

Manual derotation of the twisted spermatic cord.

Cornel EB, Karthaus HF.

BJU Int. 1999 Apr;83(6):672-4.

PMID:
10233577
17.

A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.

Tamimi Y, van der Poel HG, Karthaus HF, Debruyne FM, Schalken JA.

Br J Cancer. 1996 Aug;74(4):573-8.

18.

Laser treatment of the prostate using the Urolase fiber: the Dutch experience.

te Slaa E, Mooibroek JJ, de Reijke TM, Karthaus HF, van Capelle JW, Gi NT, de la Rosette JJ.

J Urol. 1996 Aug;156(2 Pt 1):420-4; discussion 425.

PMID:
8683693
19.

A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.

Debruyne FM, Dijkman GA, Lee DC, Witjes WP, del Moral F, Karthaus HF, van der Mejden AP, Plasman JW, Pull HC, Kums JJ, Idema JG, Hoefakker JW, Heijbroek RP, Kil PJ, Khoe GS.

J Urol. 1996 Apr;155(4):1352-4.

PMID:
8632572
20.

p53 mutations have no additional prognostic value over stage in bladder cancer.

Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA.

Br J Cancer. 1994 Sep;70(3):496-500.

21.

Ultrasonography of the spermatic cord in testicular torsion.

van Dijk R, Karthaus HF.

Eur J Radiol. 1994 Aug;18(3):220-3. No abstract available.

PMID:
7957295
22.

Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.

Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA.

Cancer Res. 1994 Jul 15;54(14):3929-33.

23.

Personality variables involved in chronic prostatitis.

de la Rosette JJ, Ruijgrok MC, Jeuken JM, Karthaus HF, Debruyne FM.

Urology. 1993 Dec;42(6):654-62. Review.

PMID:
8256399
24.

Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy.

Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, Heerschap A.

J Urol. 1993 Dec;150(6):2019-24.

PMID:
7693985
25.

Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization.

Tamimi Y, van der Poel HG, Denyn MM, Umbas R, Karthaus HF, Debruyne FM, Schalken JA.

Cancer Res. 1993 Nov 15;53(22):5512-6.

26.

Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.

Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA.

Cancer Res. 1993 Jul 15;53(14):3241-5.

27.

Work-up and management of incidentally found hypoechoic lesions of the testis.

de la Rosette JJ, Karthaus HF, Schaafsma EE, van Dijk R.

Urol Int. 1993;51(1):23-7.

PMID:
8333088
28.

Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.

Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB.

Cancer Res. 1992 Sep 15;52(18):5104-9.

29.

Ultrasonographic findings in patients with nonbacterial prostatitis.

de la Rosette JJ, Karthaus HF, Debruyne FM.

Urol Int. 1992;48(3):323-6.

PMID:
1589926
30.
32.

Carcinoma of the urinary bladder: MR imaging with a double surface coil.

Barentsz JO, Lemmens JA, Ruijs SH, Boskamp EB, Hendrikx AJ, Karthaus HF, Kaanders JH, Rosenbusch G.

AJR Am J Roentgenol. 1988 Jul;151(1):107-12.

PMID:
3259791
33.

Oncogenes and urological malignancies: implications for the future.

Schalken JA, van den Ouweland AM, Debruijne FM, Karthaus HF, Van de Ven WJ.

Urol Res. 1988;16(5):333-9. Review. No abstract available.

PMID:
3059653
34.

[Potential of magnetic resonance tomography in malignant tumors of the urinary bladder].

Barentsz JO, Ruijs JH, Karthaus HF, van Daal WA, Debruyne FM, Rosenbusch G.

Ned Tijdschr Geneeskd. 1987 Nov 28;131(48):2190-4. Dutch. No abstract available.

PMID:
3683664
35.

Multidisciplinary evaluation of rat renal cell carcinoma.

Karthaus HF, Feitz WF, vd Meijden AP, Schalken JA, Beck JL, Hendriks BT, Jap PH, Vooijs GP, Debruyne FM, Ramaekers FC.

In Vivo. 1987 Nov-Dec;1(6):335-41.

PMID:
2979800
36.

Multiparameter analysis of four human renal cell carcinoma xenografts in nude mice.

Karthaus HF, Feitz WF, Ramaekers FC, Beck JL, Hendriks BT, Schalken JA, Kurth KH, Jap PH, Debruyne FM.

In Vivo. 1987 Nov-Dec;1(6):327-34.

PMID:
2485135
37.

Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.

Schroeder FH, Lock TM, Chadha DR, Debruyne FM, Karthaus HF, de Jong FH, Klijn JG, Matroos AW, de Voogt HJ.

J Urol. 1987 May;137(5):912-8.

PMID:
2952810
38.

Expression of proto-oncogenes in xenografts of human renal cell carcinomas.

Karthaus HF, Bussemakers MJ, Schalken JA, Kurth KH, Feitz WF, Debruyne FM, Bloemers HP, Van de Ven WJ.

Urol Res. 1987;15(6):349-53.

PMID:
3324444
39.

[Percutaneous removal of kidney stones].

Strijbos WE, de Jong PC, Karthaus HF, Debruyne FM.

Ned Tijdschr Geneeskd. 1986 Mar 22;130(12):538-42. Dutch. No abstract available.

PMID:
3515207
40.

Tissue-specific markers in flow cytometry of urological cancers. II. Cytokeratin and vimentin in renal-cell tumors.

Feitz WF, Karthaus HF, Beck HL, Romijn C, van der Meyden AP, Debruyne FM, Vooijs GP, Ramaekers FC.

Int J Cancer. 1986 Feb 15;37(2):201-7.

PMID:
2417964
41.

Percutaneous removal of stones in the kidney.

Debruyne FM, Oosterhof GO, Karthaus HF.

Acta Urol Belg. 1986;54(3):245-55. No abstract available.

PMID:
3776755
42.

Expression of the human fes cellular oncogene in renal cell tumors.

Karthaus HF, Schalken JA, Feitz WF, Debruyne FM, de Haan PT, Bloemers HP, Van de Ven WJ.

Urol Res. 1986;14(3):123-7.

PMID:
3018974
43.

Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.

Debruyne FM, Karthaus HF, Schröder FH, de Voogt HJ, de Jong FH, Klijn JG.

Prog Clin Biol Res. 1985;185A:251-70. No abstract available.

PMID:
3929265
44.

An approach to undiversion in children.

Frank JD, Karthaus HF, Johnston SR, Ransley PG.

Br J Urol. 1982 Dec;54(6):700-2.

PMID:
7150928

Supplemental Content

Loading ...
Support Center